About
Life Sciences accelerator
A Cambridge-based venture builder, Start Codon has invested in 28 early stage disruptive innovations created by exceptional teams from across the UK.
Founding investors
Cambridge Innovation Capital (CIC)
CIC backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation.
Current order: Acquired order:
Babraham Research Campus
The Babraham Research Campus is a leading location which supports early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the world leading discovery research of the Babraham Institute.
Current order: Acquired order:
Dr Ian Tomlinson
Ian is a pharma R & D leader, biotech entrepreneur and antibody engineer. Ian was previously the co-founder (alongside Sir Greg Winter) and CSO for Domantis, which was sold in January 2007 to GSK for $454m. Ian has previously been SVP and Head of Worldwide Business Development for GSK and chair of both Stevenage Bioscience Catalyst and Apollo Therapeutics.
Current order: Acquired order:
Dr Jonathan Milner and Meltwind
Meltwind Advisory LLP are the due diligence and portfolio management team for Jonathan Milner, founder and former CEO of Abcam. Jonathan invests as an Angel across the life sciences, supporting companies throughout their journey with investment and guidance.
Current order: Acquired order:
Active Portfolio
Adora
Adora provides access to trusted health experts and a digital companion to ensure that every woman is guided and supported through their unique menopause journey.
Current order: Acquired order:
ArkVax
ArkVax is revolutionising animal vaccinology ArkVax aims to bring one of the safest and best proven vaccine families to animals.
Current order: Acquired order:
Awen Oncology
At Awen Oncology, we aim to transform the landscape of cancer treatment. Delivering first-in-class therapeutics that target novel, undrugged cancer-specific factors, offering new hope for patients around the world.
Current order: Acquired order:
Cardiac Tech
Cardiac Tech Ltd is a MedTech company that is creating a new safety paradigm in temporary pacing. The company’s technology is anticipated to substantially improve patient outcome and mortality post-cardiac surgery.
Current order: Acquired order:
Coding Bio
Modular therapies engineered for immune activation. We build best-in-class immunotherapies for cancer patients by testing millions of candidates to find the best therapies.
Current order: Acquired order:
CoSyne Therapeutics
We are a science-first company hacking the genetic vulnerability of brain disease.
Current order: Acquired order:
Drishti Discoveries
Drishti Discoveries is combining the powers of RNAi therapeutics and gene therapy using a proven, patented artificial microRNA technology. We are using the technology to develop a gene therapy that will achieve sustained knockdown of target gene expression.
Current order: Acquired order:
emm
Know your body with Emm. A custom fit smart menstrual product that helps you understand your body better. Track your menstrual health without lifting a finger.
Current order: Acquired order:
Enhanc3D Genomics
Our vision is to make precision medicine a reality We are a functional genomics company exploring the 3D organisation of DNA in health and disease.
Current order: Acquired order:
Erebagen
ErebaGen is a biotechnology company that harnesses the reservoir of biocatalysts developed over millions of years of evolution by Nature. Our innovative approach accelerates development and enables cost-effective, large-scale production for greener, more sustainable manufacturing solutions.
Current order: Acquired order:
Indegra Therapeutics
Indegra Therapeutics is an integrin inhibitor drug discovery platform company established in 2022 to unlock new treatments for multiple diseases with significant therapeutic and commercial benefits, including chronic kidney disease (CKD), cancer, NASH, fibrosis, osteoporosis, and eye diseases.
Current order: Acquired order:
NK:IO
Cancer treatment reimagined. Unlocking the potential of human Natural Killer cells.
Current order: Acquired order:
Octiocor
Life-saving heart attack prevention Improve patient outcomes with precision coronary imaging to detect high-risk vulnerable plaques.
Current order: Acquired order:
Proxximos
A digital solution for Infection Prevention & Control. Our products track where pathogens may have spread, enabling rapid and accurate action to prevent them infecting the next person.
Current order: Acquired order:
RevoNA
RevoNA’s innovative solution integrates a novel, patented high-throughput RNA biological platform, that rapidly amasses premium RNA datasets enriched with diverse information to feed a cutting-edge machine learning predictive engine.
Current order: Acquired order:
Semarion
A unique microcarrier platform to accelerate your cell assaying workflows
Current order: Acquired order:
Spirea
At Spirea, we are revolutionising healthcare with our unique multivalent ELIVATE linker technology. Our mission is to enable next generation ADCs that address critical unmet needs in oncology and other diseases.
Current order: Acquired order:
Spliceor
RNA splicing is an attractive therapeutic modality for treating cancer and other diseases. In contrast to cis-splicing, where two exons from the same RNA transcript are joined, RNA trans-splicing is a cellular process whereby two exons on different pre- mRNA molecules are joined together through an RNA trans-splicing reaction to produce a chimeric RNA transcript.
Current order: Acquired order:
StemBond Technologies
StemBond Technologies is redefining the potential of cell culture with advanced materials science.
Current order: Acquired order:
Tagomics
Harnessing the power of multiomics to accelerate disease understanding and diagnosis.
Current order: Acquired order:
TRIMTECH Therapeutics
TRIMTECH Therapeutics is a is a platform therapeutics company targeting selective clearance of intracellular protein assemblies, in particular the protein aggregates that characterise neurodegenerative diseases.
Current order: Acquired order:
Verinnogen
We understand the cost, time, and resources needed to evaluate new cancer therapies for clinical development. Verinnogen is committed to expediting this process by eliminating operator error in pre-clinical studies using a hand-held device to quickly and easily measure 3D objects.
Current order: Acquired order: